Part of the internationally recognized Cardiac Center at Children’s Hospital of Philadelphia (CHOP), the Topolewski Pediatric Heart Valve Center offers comprehensive, expert care and a commitment to ongoing innovation that is redefining possibilities in the field of pediatric valve repair and replacement.

Our Center has been designated as a CHOP Frontier Program. Frontier Programs are trailblazing initiatives that will forge important new discoveries, deliver novel therapies and redefine the future of pediatric medicine.

We offer:

Expertise

The Topolewski Pediatric Heart Valve Center offers your child unmatched medical and scientific expertise. Our surgical team is a world leader in pediatric valve repair and replacement for even the most complex valve disorders. Our interventional cardiologists are leaders and innovators in the area of cardiac catheterization. They've published extensively about new procedures, new devices and new options for existing devices, and are often the first to study and use cutting-edge new technologies. Our echocardiography lab is one of the largest pediatric imaging labs in the country, with over 30,000 echocardiograms performed each year and a staff of 22 physicians who specialize in state-of-the-art imaging techniques. This advanced imaging allows our surgical team to customize both surgical and catheter-based treatments to provide the best pediatric heart valve care for your child.

Innovation

Our surgical team seamlessly combines care with visionary research that is fueled by the most advanced technology in the world. From 3D heart modeling to our Cardiac Center's Virtual Reality Suite for Perioperative Planning, which uses interactive visualization to plan for and simulate surgery, we are breaking new ground and developing customized, patient-specific treatments.

Research

In addition to rapidly developing technology and personalized surgical approaches, our research is focused on identifying the genetic risk factors associated with valve disease. We hope these ongoing efforts will lead to the discovery of a first-of-its-kind pharmaceutical treatment with the potential to slow the progression of pediatric valve disease.